Results of univariate analysis comparing the rates of panel-reactive antibody positivity and donor-specific HLA antibody positivity between graft failure cases and engrafted controls
| . | Class I positive, no. (%) . | Class II positive, no. (%) . | Class I and/or II positive, no. (%) . | P . |
|---|---|---|---|---|
| Panel-reactive antibody results | > .221 | |||
| Cases (n = 37) | 16 (43) | 10 (27) | 16 (43) | |
| Controls (n = 78) | 21 (27) | 13 (17) | 25 (32) | |
| Donor-specific HLA antibodies | < .001 | |||
| Cases (n = 37) | ||||
| A: 1 (3) | DP: 6 (16) | 9 (24) | ||
| B: 4 (11) | DR: 0 (0) | |||
| C: 0 (0) | DQ: 0 (0) | |||
| Controls (n = 78) | ||||
| A: 1 (1) | DP: 1 (1) | 1 (1) | ||
| B: 0 (0) | DR: 0 (0) | |||
| C: 0 (0) | DQ: 0 (0) |
| . | Class I positive, no. (%) . | Class II positive, no. (%) . | Class I and/or II positive, no. (%) . | P . |
|---|---|---|---|---|
| Panel-reactive antibody results | > .221 | |||
| Cases (n = 37) | 16 (43) | 10 (27) | 16 (43) | |
| Controls (n = 78) | 21 (27) | 13 (17) | 25 (32) | |
| Donor-specific HLA antibodies | < .001 | |||
| Cases (n = 37) | ||||
| A: 1 (3) | DP: 6 (16) | 9 (24) | ||
| B: 4 (11) | DR: 0 (0) | |||
| C: 0 (0) | DQ: 0 (0) | |||
| Controls (n = 78) | ||||
| A: 1 (1) | DP: 1 (1) | 1 (1) | ||
| B: 0 (0) | DR: 0 (0) | |||
| C: 0 (0) | DQ: 0 (0) |